Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0Q2ES
|
||||
Former ID |
DAP000514
|
||||
Drug Name |
Benzonatate
|
||||
Synonyms |
Benzonatato; Benzonatatum; Benzononantin; Benzononatine; Exangit; Tesalon; Tessalin; Tessalon; Ventussin; Tessalon Perles; KM65; Benzonatato [INN-Spanish]; Benzonatatum [INN-Latin]; Tessalon Capsules (TN); Tessalon Perles (TN); Tessalon perles (TN); Tessalon-ciba; Ventussin-loz; Benzonatate (USP/INN); Benzonatate [USAN:INN:BAN];Nonaethyleneglycol monomethyl ether p-n-butylaminobenzoate; P-butylaminobenzoic acid omega-O-methylnonaethyleneglycol ester; Polyethyleneglycol-p-n-butylaminobenzoate methyl ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester; P-(n)-Butylaminobenzoesaeure-(nonaaethylenglykol-monomethylaether)-ester [German]; Benzoic acid, 4-(butylamino)-, 2,5,8,11,14,17,20,23,26-nonaoxaoctacos-28-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester; Benzoic acid, 4-(butylamino)-, 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester (9CI); Benzoic acid, p-(butylamino)-, 2-(2-(2-(2-(2-(2-(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethyl ester; 2,5,8,11,14,17,20,23,26-Nonaoxaoctacosan-28-yl p-(butylamino)benzoate; 2,5,8,11,14,17,20,23,26-nonaoxaoctacosan-28-yl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-(butylamino)benzoate; 2-[2-[2-[2-[2-[2-[2-[2-(2-methoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethyl 4-butylaminobenzoate; 3,6,9,12,15,18,21,24,27-Nonaoxaoctacos-1-yl 4-(butylamino)benzoate; 3,6,9,12,15,18,21,24,27-nonaoxaoctacosyl 4-butylaminobenzoate; 4-(butylamino)benzoic acid 3,6,9,12,15,18,21,24,27-nonaoxaoctacos-1-yl ester
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Antitussives
|
||||
Structure |
Download2D MOL |
||||
Formula |
C30H53NO11
|
||||
InChI |
InChI=1S/C30H53NO11/c1-3-4-9-31-29-7-5-28(6-8-29)30(32)42-27-26-41-25-24-40-23-22-39-21-20-38-19-18-37-17-16-36-15-14-35-13-12-34-11-10-33-2/h5-8,31H,3-4,9-27H2,1-2H3
|
||||
InChIKey |
MAFMQEKGGFWBAB-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 104-31-4
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
7783584, 7847308, 8155256, 11112254, 11466040, 11467160, 11485700, 16738876, 29226513, 46506376, 47574768, 47796406, 47945204, 48319874, 48415615, 49699044, 49886266, 50100399, 52308002, 56463355, 57324417, 92125009, 92740984, 103813467, 103914460, 104315714, 117583418, 121362680, 124758300, 124799565, 124882139, 125822995, 126652267, 128566573, 134224183, 134337807, 134972729, 137005903, 138413155, 144076321, 144203949, 152030785, 160964209, 163132883, 164806797, 170465391, 174510230, 175611311, 178127103, 179149334
|
||||
SuperDrug ATC ID |
R05DB01
|
||||
SuperDrug CAS ID |
cas=000104314
|
||||
Target and Pathway | |||||
Target(s) | Sodium channel protein type 5 subunit alpha | Target Info | Blocker | [536316] | |
KEGG Pathway | Adrenergic signaling in cardiomyocytes | ||||
PathWhiz Pathway | Muscle/Heart Contraction | ||||
Reactome | Interaction between L1 and Ankyrins | ||||
References | |||||
Ref 538191 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040587. | ||||
Ref 542600 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7611). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.